Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
在 HER2 低表达的乳腺癌细胞和类器官模型中,奈拉替尼作为单药疗法或与曲妥珠单抗联合疗法可能有效
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-024-02665-z
Arshad Maryam, Azad Abul, Chan Phoebe Yuen Ka, Vigneswara Vasanthy, Feldinger Katharina, Nafi Siti Norasikin Mohd, Laporte-Maguire Eloise, De Santo Carmela, Zuo Jianmin, Shaaban Abeer M, Kong Anthony